Healthcare provider profile · identity verified

Joel A Holiner, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · DALLAS, TX · NPI 1639174246

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Joel A Holiner, M.D. received $216,032.18 in general payments during 2025 across 407 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 26.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 26 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Ingrezza, Rexulti.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Auvelity by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Caplyta by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 87 records involving 83 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$216,032.18

407 reported records · 21 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$57,104.83	26.4%	60	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$42,539.95	19.7%	40	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$37,528.09	17.4%	70	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$26,261.66	12.2%	28	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$17,328.49	8.0%	32	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$8,916.84	4.1%	23	2025
Eli Lilly and Company	Unresolved — no canonical attribution shown	$7,520.37	3.5%	5	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$7,336.15	3.4%	42	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$6,964.34	3.2%	7	2025
Noven Therapeutics, LLC	Unresolved — no canonical attribution shown	$2,135.66	1.0%	6	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$760.92	0.3%	31	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$631.66	0.3%	29	2025
Corium, LLC	Unresolved — no canonical attribution shown	$246.29	0.1%	5	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$200.76	0.1%	5	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$159.26	0.1%	5	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$152.04	0.1%	7	2025
LivaNova USA, Inc.	Unresolved — no canonical attribution shown	$105.48	0.1%	4	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$69.04	0.0%	4	2025
Neos Therapeutics, LP	Unresolved — no canonical attribution shown	$34.80	0.0%	2	2025
Bausch Health US, LLC	Unresolved — no canonical attribution shown	$19.53	0.0%	1	2025
Otsuka Pharmaceutical Development & Commercialization, Inc.	Unresolved — no canonical attribution shown	$16.02	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$100,094.00	30
Honoraria	$60,976.00	21
Consulting Fee	$24,325.00	7
Travel and Lodging	$17,283.43	85
Food and Beverage	$11,253.75	261
Compensation for serving as faculty or as a speaker for a medical education program	$2,100.00	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$57,104.83	60	2025
Source payment records 2025-02-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.43 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.06 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.50 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,160.00 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.28 · Open Payments source 2025-04-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.55 · Open Payments source 2025-05-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.35 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $148.35 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $852.98 · Open Payments source 2025-06-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.89 · Open Payments source 2025-06-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $131.69 · Open Payments source 2025-06-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-06-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6,105.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $90.91 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.97 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $51.76 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,665.00 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $114.04 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $394.96 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $163.48 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,995.00 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.95 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.52 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.56 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $109.87 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-10-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.02 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $115.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $388.97 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.30 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $112.71 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $476.97 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.76 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.33 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $486.97 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $162.63 · Open Payments source 2025-11-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.64 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,665.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $69.85 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $146.90 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $47.48 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $190.49 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $899.20 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $47.54 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $103.23 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,665.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $116.67 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,995.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.48 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$37,528.09	70	2025
Source payment records 2025-02-25 · Supernus Pharmaceuticals, Inc. · $21.55 · Open Payments source 2025-03-27 · Supernus Pharmaceuticals, Inc. · $24.17 · Open Payments source 2025-04-09 · Supernus Pharmaceuticals, Inc. · $18.85 · Open Payments source 2025-05-01 · Supernus Pharmaceuticals, Inc. · $21.62 · Open Payments source 2025-05-02 · Supernus Pharmaceuticals, Inc. · $203.34 · Open Payments source 2025-05-02 · Supernus Pharmaceuticals, Inc. · $428.97 · Open Payments source 2025-05-02 · Supernus Pharmaceuticals, Inc. · $116.74 · Open Payments source 2025-05-02 · Supernus Pharmaceuticals, Inc. · $393.76 · Open Payments source 2025-05-02 · Supernus Pharmaceuticals, Inc. · $173.04 · Open Payments source 2025-05-02 · Supernus Pharmaceuticals, Inc. · $2,750.00 · Open Payments source 2025-05-02 · Supernus Pharmaceuticals, Inc. · $430.00 · Open Payments source 2025-05-03 · Supernus Pharmaceuticals, Inc. · $34.44 · Open Payments source 2025-05-03 · Supernus Pharmaceuticals, Inc. · $84.46 · Open Payments source 2025-05-03 · Supernus Pharmaceuticals, Inc. · $77.11 · Open Payments source 2025-05-03 · Supernus Pharmaceuticals, Inc. · $34.28 · Open Payments source 2025-05-03 · Supernus Pharmaceuticals, Inc. · $14.10 · Open Payments source 2025-05-08 · Supernus Pharmaceuticals, Inc. · $131.46 · Open Payments source 2025-06-18 · Supernus Pharmaceuticals, Inc. · $22.86 · Open Payments source 2025-07-24 · Supernus Pharmaceuticals, Inc. · $121.34 · Open Payments source 2025-07-24 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-07-24 · Supernus Pharmaceuticals, Inc. · $179.07 · Open Payments source 2025-07-24 · Supernus Pharmaceuticals, Inc. · $22.87 · Open Payments source 2025-07-24 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-07-30 · Supernus Pharmaceuticals, Inc. · $1,350.00 · Open Payments source 2025-08-19 · Supernus Pharmaceuticals, Inc. · $13.53 · Open Payments source 2025-08-21 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-08-21 · Supernus Pharmaceuticals, Inc. · $483.59 · Open Payments source 2025-08-27 · Supernus Pharmaceuticals, Inc. · $124.43 · Open Payments source 2025-08-27 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-08-27 · Supernus Pharmaceuticals, Inc. · $722.97 · Open Payments source 2025-08-27 · Supernus Pharmaceuticals, Inc. · $158.67 · Open Payments source 2025-08-27 · Supernus Pharmaceuticals, Inc. · $157.19 · Open Payments source 2025-08-27 · Supernus Pharmaceuticals, Inc. · $72.79 · Open Payments source 2025-08-28 · Supernus Pharmaceuticals, Inc. · $1,350.00 · Open Payments source 2025-09-11 · Supernus Pharmaceuticals, Inc. · $24.04 · Open Payments source 2025-09-23 · Supernus Pharmaceuticals, Inc. · $13.33 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $124.99 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $98.64 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $34.27 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $33.48 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $98.64 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $34.27 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $56.53 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $51.23 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $47.17 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $1,000.00 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $98.64 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $34.27 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $57.63 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $52.57 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $31.07 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $98.64 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $34.27 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $16.63 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $23.92 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $47.33 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $4,300.00 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $98.64 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $34.27 · Open Payments source 2025-10-14 · Supernus Pharmaceuticals, Inc. · $20.23 · Open Payments source 2025-10-29 · Supernus Pharmaceuticals, Inc. · $124.27 · Open Payments source 2025-10-29 · Supernus Pharmaceuticals, Inc. · $2,500.00 · Open Payments source 2025-10-29 · Supernus Pharmaceuticals, Inc. · $455.96 · Open Payments source 2025-10-29 · Supernus Pharmaceuticals, Inc. · $239.81 · Open Payments source 2025-10-29 · Supernus Pharmaceuticals, Inc. · $154.83 · Open Payments source 2025-10-29 · Supernus Pharmaceuticals, Inc. · $101.79 · Open Payments source 2025-12-02 · Supernus Pharmaceuticals, Inc. · $149.53 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$29,454.75	31	2025
Source payment records 2025-02-19 · Teva Pharmaceuticals USA, Inc. · $25.45 · Open Payments source 2025-02-20 · Teva Pharmaceuticals USA, Inc. · $41.13 · Open Payments source 2025-03-27 · Teva Pharmaceuticals USA, Inc. · $122.80 · Open Payments source 2025-03-27 · Teva Pharmaceuticals USA, Inc. · $3,251.00 · Open Payments source 2025-03-27 · Teva Pharmaceuticals USA, Inc. · $95.58 · Open Payments source 2025-05-06 · Teva Pharmaceuticals USA, Inc. · $19.93 · Open Payments source 2025-05-22 · Teva Pharmaceuticals USA, Inc. · $139.79 · Open Payments source 2025-05-22 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-05-22 · Teva Pharmaceuticals USA, Inc. · $176.11 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $48.03 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $109.28 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $212.75 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $443.37 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $5,526.00 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $107.83 · Open Payments source 2025-06-26 · Teva Pharmaceuticals USA, Inc. · $137.11 · Open Payments source 2025-06-26 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-06-26 · Teva Pharmaceuticals USA, Inc. · $64.04 · Open Payments source 2025-07-25 · Teva Pharmaceuticals USA, Inc. · $125.66 · Open Payments source 2025-07-25 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-07-25 · Teva Pharmaceuticals USA, Inc. · $79.95 · Open Payments source 2025-08-25 · Teva Pharmaceuticals USA, Inc. · $705.00 · Open Payments source 2025-09-17 · Teva Pharmaceuticals USA, Inc. · $112.95 · Open Payments source 2025-10-09 · Teva Pharmaceuticals USA, Inc. · $1,300.00 · Open Payments source 2025-11-12 · Teva Pharmaceuticals USA, Inc. · $130.86 · Open Payments source 2025-11-13 · Teva Pharmaceuticals USA, Inc. · $18.53 · Open Payments source 2025-11-14 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-11-14 · Teva Pharmaceuticals USA, Inc. · $77.87 · Open Payments source 2025-11-18 · Teva Pharmaceuticals USA, Inc. · $10.78 · Open Payments source 2025-11-18 · Teva Pharmaceuticals USA, Inc. · $122.95 · Open Payments source 2025-11-18 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$26,261.66	28	2025
Source payment records 2025-03-15 · Axsome Therapeutics, Inc. · $48.79 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $32.93 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $26.77 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $29.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $78.04 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $45.30 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $234.83 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $422.98 · Open Payments source 2025-03-18 · Axsome Therapeutics, Inc. · $17.52 · Open Payments source 2025-04-03 · Axsome Therapeutics, Inc. · $8,775.00 · Open Payments source 2025-04-04 · Axsome Therapeutics, Inc. · $87.44 · Open Payments source 2025-04-04 · Axsome Therapeutics, Inc. · $123.93 · Open Payments source 2025-04-24 · Axsome Therapeutics, Inc. · $3,038.00 · Open Payments source 2025-04-24 · Axsome Therapeutics, Inc. · $121.86 · Open Payments source 2025-04-24 · Axsome Therapeutics, Inc. · $90.75 · Open Payments source 2025-08-29 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-08-29 · Axsome Therapeutics, Inc. · $7.35 · Open Payments source 2025-11-10 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-11-12 · Axsome Therapeutics, Inc. · $15.24 · Open Payments source 2025-12-08 · Axsome Therapeutics, Inc. · $22.99 · Open Payments source 2025-12-09 · Axsome Therapeutics, Inc. · $5,738.00 · Open Payments source 2025-12-09 · Axsome Therapeutics, Inc. · $63.74 · Open Payments source 2025-12-09 · Axsome Therapeutics, Inc. · $115.65 · Open Payments source 2025-12-09 · Axsome Therapeutics, Inc. · $194.35 · Open Payments source 2025-12-09 · Axsome Therapeutics, Inc. · $645.96 · Open Payments source 2025-12-09 · Axsome Therapeutics, Inc. · $197.19 · Open Payments source 2025-12-11 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-12-11 · Axsome Therapeutics, Inc. · $12.60 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$17,328.49	32	2025
Source payment records 2025-05-05 · Vanda Pharmaceuticals Inc. · $22.65 · Open Payments source 2025-06-20 · Vanda Pharmaceuticals Inc. · $5.95 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $178.12 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $705.96 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $5,670.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $225.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $101.11 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $219.22 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $103.34 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $69.90 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $3.99 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $29.52 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $32.61 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $49.55 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $79.73 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $2.66 · Open Payments source 2025-08-18 · Vanda Pharmaceuticals Inc. · $3.70 · Open Payments source 2025-09-22 · Vanda Pharmaceuticals Inc. · $18.53 · Open Payments source 2025-10-12 · Vanda Pharmaceuticals Inc. · $11.67 · Open Payments source 2025-10-22 · Vanda Pharmaceuticals Inc. · $22.70 · Open Payments source 2025-10-22 · Vanda Pharmaceuticals Inc. · $2,100.00 · Open Payments source 2025-10-22 · Vanda Pharmaceuticals Inc. · $518.87 · Open Payments source 2025-10-23 · Vanda Pharmaceuticals Inc. · $19.89 · Open Payments source 2025-10-23 · Vanda Pharmaceuticals Inc. · $120.13 · Open Payments source 2025-10-23 · Vanda Pharmaceuticals Inc. · $2,520.00 · Open Payments source 2025-10-23 · Vanda Pharmaceuticals Inc. · $108.08 · Open Payments source 2025-11-11 · Vanda Pharmaceuticals Inc. · $14.02 · Open Payments source 2025-11-11 · Vanda Pharmaceuticals Inc. · $2,100.00 · Open Payments source 2025-11-11 · Vanda Pharmaceuticals Inc. · $61.48 · Open Payments source 2025-11-25 · Vanda Pharmaceuticals Inc. · $23.74 · Open Payments source 2025-11-25 · Vanda Pharmaceuticals Inc. · $2,100.00 · Open Payments source 2025-11-25 · Vanda Pharmaceuticals Inc. · $86.37 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$13,085.20	9	2025
Source payment records 2025-03-30 · Teva Pharmaceuticals USA, Inc. · $8,893.00 · Open Payments source 2025-04-09 · Teva Pharmaceuticals USA, Inc. · $127.30 · Open Payments source 2025-10-27 · Teva Pharmaceuticals USA, Inc. · $12.34 · Open Payments source 2025-11-03 · Teva Pharmaceuticals USA, Inc. · $11.49 · Open Payments source 2025-11-30 · Teva Pharmaceuticals USA, Inc. · $574.00 · Open Payments source 2025-12-01 · Teva Pharmaceuticals USA, Inc. · $12.34 · Open Payments source 2025-12-10 · Teva Pharmaceuticals USA, Inc. · $127.06 · Open Payments source 2025-12-10 · Teva Pharmaceuticals USA, Inc. · $3,250.00 · Open Payments source 2025-12-10 · Teva Pharmaceuticals USA, Inc. · $77.67 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$8,916.84	23	2025
Source payment records 2025-01-21 · Alkermes, Inc. · $31.48 · Open Payments source 2025-04-04 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-04 · Alkermes, Inc. · $125.00 · Open Payments source 2025-04-04 · Alkermes, Inc. · $24.95 · Open Payments source 2025-04-05 · Alkermes, Inc. · $291.96 · Open Payments source 2025-04-05 · Alkermes, Inc. · $238.26 · Open Payments source 2025-04-05 · Alkermes, Inc. · $2.88 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-05 · Alkermes, Inc. · $60.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $48.66 · Open Payments source 2025-04-05 · Alkermes, Inc. · $75.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $17.85 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.00 · Open Payments source 2025-04-24 · Alkermes, Inc. · $6,500.00 · Open Payments source 2025-05-19 · Alkermes, Inc. · $89.16 · Open Payments source 2025-05-21 · Alkermes, Inc. · $36.91 · Open Payments source 2025-05-21 · Alkermes, Inc. · $62.93 · Open Payments source 2025-08-05 · Alkermes, Inc. · $7.98 · Open Payments source 2025-08-13 · Alkermes, Inc. · $960.00 · Open Payments source 2025-09-03 · Alkermes, Inc. · $127.92 · Open Payments source 2025-09-15 · Alkermes, Inc. · $10.59 · Open Payments source 2025-11-11 · Alkermes, Inc. · $13.73 · Open Payments source 2025-12-16 · Alkermes, Inc. · $122.04 · Open Payments source
Dyanavel XR Normalized: dyanavel xr	Drug	Tris Pharma Inc	$6,964.34	7	2025
Source payment records 2025-03-27 · Tris Pharma Inc · $92.34 · Open Payments source 2025-04-21 · Tris Pharma Inc · $3,300.00 · Open Payments source 2025-05-06 · Tris Pharma Inc · $13.84 · Open Payments source 2025-09-11 · Tris Pharma Inc · $125.00 · Open Payments source 2025-09-11 · Tris Pharma Inc · $125.00 · Open Payments source 2025-10-01 · Tris Pharma Inc · $3,300.00 · Open Payments source 2025-12-15 · Tris Pharma Inc · $8.16 · Open Payments source
Quillichew ER Normalized: quillichew er	Drug	Tris Pharma Inc	$6,850.00	4	2025
Source payment records 2025-04-21 · Tris Pharma Inc · $3,300.00 · Open Payments source 2025-09-11 · Tris Pharma Inc · $125.00 · Open Payments source 2025-09-11 · Tris Pharma Inc · $125.00 · Open Payments source 2025-10-01 · Tris Pharma Inc · $3,300.00 · Open Payments source
Quillivant Normalized: quillivant	Drug	Tris Pharma Inc	$6,850.00	4	2025
Source payment records 2025-04-21 · Tris Pharma Inc · $3,300.00 · Open Payments source 2025-09-11 · Tris Pharma Inc · $125.00 · Open Payments source 2025-09-11 · Tris Pharma Inc · $125.00 · Open Payments source 2025-10-01 · Tris Pharma Inc · $3,300.00 · Open Payments source
Xelstrym Normalized: xelstrym	Drug	Noven Therapeutics, LLC	$2,135.66	6	2025
Source payment records 2025-04-10 · Noven Therapeutics, LLC · $10.94 · Open Payments source 2025-06-04 · Noven Therapeutics, LLC · $525.00 · Open Payments source 2025-07-09 · Noven Therapeutics, LLC · $525.00 · Open Payments source 2025-08-14 · Noven Therapeutics, LLC · $1,050.00 · Open Payments source 2025-09-12 · Noven Therapeutics, LLC · $11.99 · Open Payments source 2025-11-24 · Noven Therapeutics, LLC · $12.73 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$979.97	29	2025
Source payment records 2025-01-28 · E.R. Squibb & Sons, L.L.C. · $22.45 · Open Payments source 2025-01-28 · E.R. Squibb & Sons, L.L.C. · $15.98 · Open Payments source 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $4.26 · Open Payments source 2025-02-04 · E.R. Squibb & Sons, L.L.C. · $6.27 · Open Payments source 2025-02-20 · E.R. Squibb & Sons, L.L.C. · $28.52 · Open Payments source 2025-02-27 · E.R. Squibb & Sons, L.L.C. · $110.40 · Open Payments source 2025-03-04 · E.R. Squibb & Sons, L.L.C. · $4.21 · Open Payments source 2025-03-18 · E.R. Squibb & Sons, L.L.C. · $132.37 · Open Payments source 2025-04-08 · E.R. Squibb & Sons, L.L.C. · $5.99 · Open Payments source 2025-04-08 · E.R. Squibb & Sons, L.L.C. · $3.13 · Open Payments source 2025-04-22 · E.R. Squibb & Sons, L.L.C. · $22.82 · Open Payments source 2025-05-13 · E.R. Squibb & Sons, L.L.C. · $13.92 · Open Payments source 2025-05-19 · E.R. Squibb & Sons, L.L.C. · $144.90 · Open Payments source 2025-06-11 · E.R. Squibb & Sons, L.L.C. · $24.65 · Open Payments source 2025-06-26 · E.R. Squibb & Sons, L.L.C. · $22.35 · Open Payments source 2025-07-03 · E.R. Squibb & Sons, L.L.C. · $113.18 · Open Payments source 2025-07-10 · E.R. Squibb & Sons, L.L.C. · $13.10 · Open Payments source 2025-07-24 · E.R. Squibb & Sons, L.L.C. · $7.19 · Open Payments source 2025-08-07 · E.R. Squibb & Sons, L.L.C. · $16.93 · Open Payments source 2025-08-11 · E.R. Squibb & Sons, L.L.C. · $14.13 · Open Payments source 2025-08-20 · E.R. Squibb & Sons, L.L.C. · $121.84 · Open Payments source 2025-08-21 · E.R. Squibb & Sons, L.L.C. · $20.90 · Open Payments source 2025-09-02 · E.R. Squibb & Sons, L.L.C. · $13.54 · Open Payments source 2025-09-16 · E.R. Squibb & Sons, L.L.C. · $13.10 · Open Payments source 2025-10-16 · E.R. Squibb & Sons, L.L.C. · $21.84 · Open Payments source 2025-11-11 · E.R. Squibb & Sons, L.L.C. · $22.12 · Open Payments source 2025-11-25 · E.R. Squibb & Sons, L.L.C. · $20.00 · Open Payments source 2025-12-18 · E.R. Squibb & Sons, L.L.C. · $16.50 · Open Payments source 2025-12-18 · E.R. Squibb & Sons, L.L.C. · $3.38 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$760.92	31	2025
Source payment records 2025-01-13 · Neurocrine BioSciences, Inc. · $33.07 · Open Payments source 2025-01-27 · Neurocrine BioSciences, Inc. · $30.89 · Open Payments source 2025-03-25 · Neurocrine BioSciences, Inc. · $27.64 · Open Payments source 2025-04-08 · Neurocrine BioSciences, Inc. · $39.20 · Open Payments source 2025-04-23 · Neurocrine BioSciences, Inc. · $24.52 · Open Payments source 2025-04-29 · Neurocrine BioSciences, Inc. · $14.73 · Open Payments source 2025-05-02 · Neurocrine BioSciences, Inc. · $10.66 · Open Payments source 2025-05-14 · Neurocrine BioSciences, Inc. · $10.75 · Open Payments source 2025-05-15 · Neurocrine BioSciences, Inc. · $10.05 · Open Payments source 2025-05-19 · Neurocrine BioSciences, Inc. · $36.95 · Open Payments source 2025-05-23 · Neurocrine BioSciences, Inc. · $9.88 · Open Payments source 2025-05-27 · Neurocrine BioSciences, Inc. · $31.58 · Open Payments source 2025-06-06 · Neurocrine BioSciences, Inc. · $11.25 · Open Payments source 2025-06-10 · Neurocrine BioSciences, Inc. · $29.63 · Open Payments source 2025-06-12 · Neurocrine BioSciences, Inc. · $20.42 · Open Payments source 2025-06-27 · Neurocrine BioSciences, Inc. · $12.36 · Open Payments source 2025-07-16 · Neurocrine BioSciences, Inc. · $8.69 · Open Payments source 2025-07-22 · Neurocrine BioSciences, Inc. · $25.00 · Open Payments source 2025-07-25 · Neurocrine BioSciences, Inc. · $13.64 · Open Payments source 2025-07-29 · Neurocrine BioSciences, Inc. · $25.17 · Open Payments source 2025-09-02 · Neurocrine BioSciences, Inc. · $32.79 · Open Payments source 2025-09-04 · Neurocrine BioSciences, Inc. · $134.84 · Open Payments source 2025-09-05 · Neurocrine BioSciences, Inc. · $14.62 · Open Payments source 2025-10-17 · Neurocrine BioSciences, Inc. · $14.02 · Open Payments source 2025-10-28 · Neurocrine BioSciences, Inc. · $23.19 · Open Payments source 2025-11-05 · Neurocrine BioSciences, Inc. · $31.43 · Open Payments source 2025-11-21 · Neurocrine BioSciences, Inc. · $10.10 · Open Payments source 2025-12-01 · Neurocrine BioSciences, Inc. · $11.17 · Open Payments source 2025-12-10 · Neurocrine BioSciences, Inc. · $28.78 · Open Payments source 2025-12-18 · Neurocrine BioSciences, Inc. · $31.65 · Open Payments source 2025-12-18 · Neurocrine BioSciences, Inc. · $2.25 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$631.66	29	2025
Source payment records 2025-01-08 · ABBVIE INC. · $25.97 · Open Payments source 2025-01-15 · ABBVIE INC. · $18.21 · Open Payments source 2025-01-29 · ABBVIE INC. · $19.20 · Open Payments source 2025-02-05 · ABBVIE INC. · $7.30 · Open Payments source 2025-02-27 · ABBVIE INC. · $21.35 · Open Payments source 2025-03-05 · ABBVIE INC. · $2.76 · Open Payments source 2025-03-06 · ABBVIE INC. · $124.99 · Open Payments source 2025-03-12 · ABBVIE INC. · $100.00 · Open Payments source 2025-03-26 · ABBVIE INC. · $17.14 · Open Payments source 2025-04-02 · ABBVIE INC. · $12.01 · Open Payments source 2025-04-08 · ABBVIE INC. · $16.05 · Open Payments source 2025-04-16 · ABBVIE INC. · $5.43 · Open Payments source 2025-05-07 · ABBVIE INC. · $4.53 · Open Payments source 2025-05-14 · ABBVIE INC. · $15.86 · Open Payments source 2025-05-18 · ABBVIE INC. · $39.23 · Open Payments source 2025-05-21 · ABBVIE INC. · $5.48 · Open Payments source 2025-06-18 · ABBVIE INC. · $9.66 · Open Payments source 2025-07-02 · ABBVIE INC. · $23.34 · Open Payments source 2025-07-09 · ABBVIE INC. · $13.37 · Open Payments source 2025-07-30 · ABBVIE INC. · $19.19 · Open Payments source 2025-08-13 · ABBVIE INC. · $17.24 · Open Payments source 2025-09-03 · ABBVIE INC. · $20.46 · Open Payments source 2025-10-01 · ABBVIE INC. · $19.16 · Open Payments source 2025-10-13 · ABBVIE INC. · $11.54 · Open Payments source 2025-10-15 · ABBVIE INC. · $9.00 · Open Payments source 2025-10-29 · ABBVIE INC. · $19.70 · Open Payments source 2025-11-05 · ABBVIE INC. · $19.70 · Open Payments source 2025-12-03 · ABBVIE INC. · $8.18 · Open Payments source 2025-12-17 · ABBVIE INC. · $5.61 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$246.29	5	2025
Source payment records 2025-05-29 · Corium, LLC · $18.26 · Open Payments source 2025-06-30 · Corium, LLC · $24.21 · Open Payments source 2025-07-31 · Corium, LLC · $148.33 · Open Payments source 2025-11-06 · Corium, LLC · $31.40 · Open Payments source 2025-12-03 · Corium, LLC · $24.09 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$178.48	9	2025
Source payment records 2025-01-06 · Otsuka America Pharmaceutical, Inc. · $18.31 · Open Payments source 2025-01-07 · Lundbeck LLC · $21.65 · Open Payments source 2025-02-12 · Lundbeck LLC · $20.42 · Open Payments source 2025-04-21 · Lundbeck LLC · $26.52 · Open Payments source 2025-06-23 · Otsuka America Pharmaceutical, Inc. · $15.35 · Open Payments source 2025-07-14 · Otsuka America Pharmaceutical, Inc. · $18.36 · Open Payments source 2025-07-23 · Lundbeck LLC · $19.63 · Open Payments source 2025-08-20 · Lundbeck LLC · $21.22 · Open Payments source 2025-11-03 · Otsuka America Pharmaceutical, Inc. · $17.02 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$175.45	3	2025
Source payment records 2025-02-21 · Janssen Pharmaceuticals, Inc · $148.25 · Open Payments source 2025-07-08 · Janssen Pharmaceuticals, Inc · $18.68 · Open Payments source 2025-09-10 · Janssen Pharmaceuticals, Inc · $8.52 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$159.26	5	2025
Source payment records 2025-01-15 · Collegium Pharmaceutical, Inc. · $9.09 · Open Payments source 2025-01-27 · Collegium Pharmaceutical, Inc. · $9.24 · Open Payments source 2025-08-07 · Collegium Pharmaceutical, Inc. · $123.93 · Open Payments source 2025-09-08 · Collegium Pharmaceutical, Inc. · $8.86 · Open Payments source 2025-10-09 · Collegium Pharmaceutical, Inc. · $8.14 · Open Payments source
VNS THERAPY SYMMETRY MODEL 8103 GENERATOR Normalized: vns therapy symmetry model 8103 generator	Device	LivaNova USA, Inc.	$105.48	4	2025
Source payment records 2025-04-16 · LivaNova USA, Inc. · $25.05 · Open Payments source 2025-05-20 · LivaNova USA, Inc. · $19.85 · Open Payments source 2025-09-25 · LivaNova USA, Inc. · $30.29 · Open Payments source 2025-11-18 · LivaNova USA, Inc. · $30.29 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$63.78	4	2025
Source payment records 2025-01-21 · Alkermes, Inc. · $31.48 · Open Payments source 2025-08-05 · Alkermes, Inc. · $7.98 · Open Payments source 2025-09-15 · Alkermes, Inc. · $10.59 · Open Payments source 2025-11-11 · Alkermes, Inc. · $13.73 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Lundbeck LLC	$42.60	2	2025
Source payment records 2025-06-25 · Lundbeck LLC · $20.84 · Open Payments source 2025-09-24 · Lundbeck LLC · $21.76 · Open Payments source
Secuado Normalized: secuado	Drug	Noven Therapeutics, LLC	$35.66	3	2025
Source payment records 2025-04-10 · Noven Therapeutics, LLC · $10.94 · Open Payments source 2025-09-12 · Noven Therapeutics, LLC · $11.99 · Open Payments source 2025-11-24 · Noven Therapeutics, LLC · $12.73 · Open Payments source
Adzenys XR-ODT Normalized: adzenys xr odt	Drug	Neos Therapeutics, LP	$34.80	2	2025
Source payment records 2025-06-08 · Neos Therapeutics, LP · $15.83 · Open Payments source 2025-09-08 · Neos Therapeutics, LP · $18.97 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$25.31	2	2025
Source payment records 2025-05-21 · Janssen Pharmaceuticals, Inc · $15.10 · Open Payments source 2025-10-14 · Janssen Pharmaceuticals, Inc · $10.21 · Open Payments source
APLENZIN Normalized: aplenzin	Drug	Bausch Health US, LLC	$19.53	1	2025
Source payment records 2025-09-08 · Bausch Health US, LLC · $19.53 · Open Payments source
WELLBUTRIN Normalized: wellbutrin	Drug	Bausch Health US, LLC	$19.53	1	2025
Source payment records 2025-09-08 · Bausch Health US, LLC · $19.53 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Auvelity auvelity	2025	Auvelity	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	29 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	17 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	13 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	29	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	29	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 87 supporting records · 83 recipient NPIs · example record 1225319985	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865	Rexulti · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	333	66
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	185	42
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	155	20
Trazodone Hcl	Trazodone Hcl	107	51
Alprazolam	Alprazolam	104	42
Lamotrigine	Lamotrigine	100	42
Buspirone Hcl	Buspirone Hcl	87	32
Clonazepam	Clonazepam	84	40
Clozapine	Clozapine	75	13
Aripiprazole	Aripiprazole	69	18
Bupropion Xl	Bupropion Hcl	63	35
Duloxetine Hcl	Duloxetine Hcl	61	23
Gabapentin	Gabapentin	58	18
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	54	16
Sertraline Hcl	Sertraline Hcl	54	26
Zolpidem Tartrate	Zolpidem Tartrate	50	18
Vyvanse	Lisdexamfetamine Dimesylate	49	14
Lorazepam	Lorazepam	46	16
Quetiapine Fumarate	Quetiapine Fumarate	46	21
Escitalopram Oxalate	Escitalopram Oxalate	44	22
Methylphenidate Hcl	Methylphenidate Hcl	41	13
Belsomra	Suvorexant	37	suppressed
Caplyta	Lumateperone Tosylate	29	suppressed
Eszopiclone	Eszopiclone	27	suppressed
Temazepam	Temazepam	26	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	25	15
Oxcarbazepine	Oxcarbazepine	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	11
Suboxone	Buprenorphine Hcl/Naloxone Hcl	22	suppressed
Divalproex Sodium Er	Divalproex Sodium	21	suppressed
Lithium Carbonate	Lithium Carbonate	20	suppressed
Mirtazapine	Mirtazapine	20	12
Doxepin Hcl	Doxepin Hcl	18	suppressed
Prazosin Hcl	Prazosin Hcl	18	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	18	suppressed
Ingrezza	Valbenazine Tosylate	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Lurasidone Hcl	Lurasidone Hcl	15	suppressed
Trintellix	Vortioxetine Hydrobromide	15	suppressed
Dexmethylphenidate Hcl Er	Dexmethylphenidate Hcl	14	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Lithium Carbonate Er	Lithium Carbonate	14	suppressed
Abilify Maintena	Aripiprazole	13	suppressed
Adderall Xr	Dextroamphetamine/Amphetamine	13	suppressed
Emsam	Selegiline	13	suppressed
Rexulti	Brexpiprazole	13	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	13	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	12	suppressed
Focalin Xr	Dexmethylphenidate Hcl	12	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	12	suppressed
Diazepam	Diazepam	11	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Paliperidone Er	Paliperidone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$216,032.18 · 407 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, APLENZIN, ARISTADA, AUSTEDO XR, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Qelbree, Quillichew ER, Quillivant, REXULTI, SPRAVATO, Secuado, UZEDY, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR, VRAYLAR, WELLBUTRIN, Xelstrym	10	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Auvelity play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Axsome Therapeutics, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error